PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions

Footnotes and References

a.assessment based on product information accessed via the Therapeutic Goods Administration of Australia Product and Consumer Medicines Information website ( https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=PI&q=&r=https://www.ebs.tga.gov.au/ ).
1.Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L, Gustafsson LL. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European Journal of Clinical Pharmacology 2006; 62: 539-46.[PubMed]
2.Robertson P, Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. Journal of Clinical Pharmacology 2002; 42: 205-14.[PubMed]
3.Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. British Journal of Clinical Pharmacology 1993; 36: 380-82.[PubMed]
4.Breimer DD, Zilly W, Richter E. Influence of corticosteroid on hexobarbital and tolbutamide disposition. Clinical Pharmacology & Therapeutics 1978; 24: 208-12.[PubMed]
5.Wang ZQ, Gorski C, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology & Therapeutics 2001; 70: 317-26.[PubMed]
Disclaimer
WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.